Caribou Biosciences, Inc. SEC filings CRBU
Caribou Biosciences, Inc. has 324 filings in SEC EDGAR's recent list, going back to Sep 23, 2014. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (exit or restructuring costs, officer or director change, regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure, Other events
|
Oct 6, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Jun 5, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| DEFR14A | Filing | May 1, 2026 | — |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Dec 31, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 31, 2026 | Mar 31, 2026 |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Nov 3, 2025 | Nov 3, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Other events
|
Jun 23, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 12, 2025 |
| EFFECT | Filing | May 14, 2025 | — |
| CORRESP | Letter to the SEC | May 13, 2025 | — |
| UPLOAD | Letter from the SEC | May 12, 2025 | — |
| DEFA14A | Additional proxy material | May 8, 2025 | — |
| S-3 | Shelf registration | May 8, 2025 | — |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Other events
|
Apr 24, 2025 | Apr 24, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2025 | Dec 31, 2024 |
| S-8 | Employee stock plan registration | Mar 10, 2025 | — |
| 10-K | Annual report | Mar 10, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 2, 2025 | Jan 2, 2025 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K/A |
Amended current report
Officer or director change
|
Sep 27, 2024 | Sep 1, 2024 |
| 8-K |
Current report
Officer or director change
|
Sep 3, 2024 | Sep 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 12, 2024 | Aug 12, 2024 |
| 10-Q | Quarterly report | Aug 6, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
Jul 16, 2024 | Jul 16, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 3, 2024 | Jun 2, 2024 |
| 10-Q | Quarterly report | May 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| ARS | Annual report to shareholders | Apr 25, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 4, 2024 | Apr 4, 2024 |
| S-8 | Employee stock plan registration | Mar 11, 2024 | — |
| 10-K | Annual report | Mar 11, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2024 | Mar 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 8, 2024 | Jan 7, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 22, 2023 | Dec 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Dec 12, 2023 | Dec 11, 2023 |
| 10-Q/A | Amended quarterly report | Nov 17, 2023 | Jun 30, 2023 |
| 10-Q/A | Amended quarterly report | Nov 17, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 7, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 18, 2023 | Oct 18, 2023 |
| 8-K |
Current report
Agreement ended
|
Sep 26, 2023 | Sep 26, 2023 |
| 10-Q | Quarterly report | Aug 8, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Material agreement
|
Jul 17, 2023 | Jul 13, 2023 |
| 424B5 | Prospectus supplement | Jul 14, 2023 | — |
| 8-K/A |
Amended current report
Other events
|
Jul 14, 2023 | Jul 13, 2023 |
| 424B5 | Prospectus supplement | Jul 13, 2023 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 13, 2023 | Jul 13, 2023 |
| 8-K |
Current report
Other events
|
Jul 13, 2023 | Jul 13, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Jul 6, 2023 | Jun 29, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2023 | Jun 15, 2023 |
| 10-Q | Quarterly report | May 9, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 4, 2023 | Apr 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 29, 2023 | Mar 29, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 29, 2023 | Mar 29, 2023 |
| 8-K |
Current report
Other events
|
Mar 24, 2023 | Mar 24, 2023 |
| S-8 | Employee stock plan registration | Mar 9, 2023 | — |
| 10-K | Annual report | Mar 9, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2023 | Mar 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 16, 2022 | Dec 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 12, 2022 | Dec 12, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 29, 2022 | Nov 29, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 21, 2022 | Nov 21, 2022 |
| 10-Q | Quarterly report | Nov 8, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2022 | Nov 8, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 18, 2022 | Oct 18, 2022 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Sep 23, 2022 | Sep 20, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Sep 22, 2022 | Sep 21, 2022 |
| EFFECT | Filing | Aug 16, 2022 | — |
| CORRESP | Letter to the SEC | Aug 12, 2022 | — |
| 8-K |
Current report
Material agreement
|
Aug 12, 2022 | Aug 9, 2022 |
| UPLOAD | Letter from the SEC | Aug 11, 2022 | — |
| DEFA14A | Additional proxy material | Aug 11, 2022 | — |
| DEFA14A | Additional proxy material | Aug 11, 2022 | — |
| DEF 14A | Proxy statement | Aug 11, 2022 | Aug 11, 2022 |
| S-3 | Shelf registration | Aug 9, 2022 | — |
| 10-Q | Quarterly report | Aug 9, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 18, 2022 | May 11, 2022 |
| 8-K |
Current report
Other events
|
Jul 15, 2022 | Jul 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 10, 2022 | Jun 10, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 1, 2022 | Jun 1, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 11, 2022 | May 10, 2022 |
| 10-Q | Quarterly report | May 9, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 9, 2022 | May 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 25, 2022 | Apr 25, 2022 |
| S-8 | Employee stock plan registration | Mar 21, 2022 | — |
| 10-K | Annual report | Mar 21, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2022 | Mar 21, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Jan 19, 2022 | Jan 13, 2022 |
| 8-K |
Current report
Other events
|
Jan 18, 2022 | Jan 18, 2022 |
| 10-Q | Quarterly report | Nov 9, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 8, 2021 | Nov 4, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 29, 2021 | Sep 24, 2021 |
| 10-Q | Quarterly report | Sep 2, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Sep 2, 2021 | Sep 2, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 25, 2021 | Aug 24, 2021 |
| 8-K |
Current report
Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Jul 28, 2021 | Jul 22, 2021 |
| S-8 | Employee stock plan registration | Jul 26, 2021 | — |
| 424B4 | Prospectus | Jul 23, 2021 | — |
| EFFECT | Filing | Jul 22, 2021 | — |
| S-1MEF | Filing | Jul 22, 2021 | — |
| SEC STAFF LETTER | Filing | Jul 22, 2021 | — |
| FWP | Free writing prospectus | Jul 22, 2021 | — |
| S-1/A | Amended registration statement | Jul 22, 2021 | — |
| CERT | Filing | Jul 21, 2021 | — |
| CORRESP | Letter to the SEC | Jul 20, 2021 | — |
| CORRESP | Letter to the SEC | Jul 20, 2021 | — |
| 8-A12B | Filing | Jul 19, 2021 | — |
| S-1/A | Amended registration statement | Jul 19, 2021 | — |
| CORRESP | Letter to the SEC | Jul 12, 2021 | — |
| CORRESP | Letter to the SEC | Jul 1, 2021 | — |
| S-1 | Registration statement | Jul 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2021 | — |
| DRSLTR | Filing | Jun 11, 2021 | — |
| DRS/A | Filing | Jun 11, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2021 | — |
| SEC STAFF LETTER | Filing | May 18, 2021 | — |
| DRS | Filing | May 7, 2021 | — |
| D | Filing | Mar 5, 2021 | — |
| D | Filing | May 25, 2016 | — |
| D/A | Filing | Mar 24, 2015 | — |
| D | Filing | Sep 23, 2014 | — |
Showing 158 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRBU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1619856
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.